Recurrent Hairy Cell Leukemia: Clinical Trials

4 trials for Recurrent Hairy Cell Leukemia, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 active not recruiting, 2 recruiting. 4 Phase 2, 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 24Active not recruiting 2, Recruiting 2
Phase 11Recruiting 1

Follow Recurrent Hairy Cell Leukemia: new trials by email Literature Review of Recurrent Hairy Cell Leukemia trials Research Report on Recurrent Hairy Cell Leukemia

Trials (filtered) newest first · largest first

All 4 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Hairy Cell Leukemia, Recurrent Hairy Cell Leukemia
Phase 1 / Phase 2RecruitingNational Cancer Institute (NCI)842026-05-292026-07-31
Venetoclax for the Treatment of Patients With Relapsed Hairy Cell Leukemia
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Hairy Cell Leukemia, Recurrent Hairy Cell Leukemia Variant
Phase 2Active not recruitingNational Cancer Institute (NCI)202024-12-162026-09-09
Ibrutinib in Treating Patients With Relapsed Hairy Cell Leukemia
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Hairy Cell Leukemia, Hairy Cell Leukemia Variant
Phase 2Active not recruitingNational Cancer Institute (NCI)442013-04-302026-11-12
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
Cladribine, Laboratory Biomarker Analysis, Rituximab - Hairy Cell Leukemia, Recurrent Hairy Cell Leukemia
Phase 2RecruitingM.D. Anderson Cancer Center1502004-06-102026-06-11

Narrower conditions

Leukemia, Hairy Cell (4)

Broader conditions

Hematologic Diseases (4)  ·  Hemic and Lymphatic Diseases (4)  ·  Immune System Diseases (4)  ·  Immunoproliferative Disorders (4)  ·  Leukemia (4)  ·  Lymphatic Diseases (4)  ·  Lymphoproliferative Disorders (4)  ·  Neoplasms (4)  ·  Neoplasms by Histologic Type (4)

Interventions

Biopsy (3)  ·  Specimen Handling (3)  ·  CT-P10 (2)  ·  Cladribine (2)  ·  Rituximab (2)  ·  High-Energy Shock Waves (1)  ·  Magnetic Resonance Spectroscopy (1)  ·  Spinal Puncture (1)  ·  ibrutinib (1)  ·  tovorafenib (1)  ·  venetoclax (1)

Sponsors

National Cancer Institute (NCI) (3)  ·  M.D. Anderson Cancer Center (1)

Countries

United States (4)

Top investigators

Farhad Ravandi-Kashani (1)  ·  Kerry A Rogers (1)  ·  Robert J Kreitman (1)  ·  Seema A Bhat (1)

Results publications

PMID 21821712, PMID 33754642, PMID 41980020

NIH funding

UM1CA186712 (2), N01CM00039 (1), P30CA016058 (1), U01CA076576 (1)